You are here

Category: Most Recent

Cardiovascular risk profile among patients with inflammatory bowel disease: a population-based study of >100,000 individuals.

ibdwatch

Cardiovascular risk profile among patients with inflammatory bowel disease: a population-based study of >100,000 individuals. J Crohns Colitis. 2018 Oct 13;: Authors: Aarestrup J, Jess T, Kobylecki CJ, Nordestgaard BG, Allin KH Abstract Background and Aims: Patients with inflammatory bowel disease have increased risks of cardiovascular diseases but the role of traditional and non-traditional cardiovascular risk factors remains unclear. We investigated if the cardiovascular risk profile differs between patients with inflammatory bowel disease and individuals in the general population. Methods: We included a population of 108,789 participants from The Copenhagen…

Read More

An Increased Abundance of Clostridiaceae Characterizes Arthritis in Inflammatory Bowel Disease and Rheumatoid Arthritis: A Cross-sectional Study.

ibdwatch

An Increased Abundance of Clostridiaceae Characterizes Arthritis in Inflammatory Bowel Disease and Rheumatoid Arthritis: A Cross-sectional Study. Inflamm Bowel Dis. 2018 Oct 12;: Authors: Muñiz Pedrogo DA, Chen J, Hillmann B, Jeraldo P, Al-Ghalith G, Taneja V, Davis JM, Knights D, Nelson H, Faubion WA, Raffals L, Kashyap PC Abstract Background: Inflammatory bowel diseases (IBDs) are a group of heterogeneous inflammatory conditions affecting the gastrointestinal tract. Although there is considerable evidence linking the gut microbiota to intestinal inflammation, there is limited knowledge on its potential role in the development of…

Read More

Letter: is there a role for infliximab biosimilar in patients with inflammatory bowel disease with secondary loss of response to infliximab innovator?

ibdwatch

Related Articles Letter: is there a role for infliximab biosimilar in patients with inflammatory bowel disease with secondary loss of response to infliximab innovator? Aliment Pharmacol Ther. 2018 Nov;48(9):1037-1038 Authors: Orfanoudaki E, Drygiannakis I, Koutroubakis IE PMID: 30318690 [PubMed – in process] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/30318690?dopt=Abstract

Read More

Immunosuppression Does Not Affect Antibody Concentrations to Measles, Mumps, and Rubella in Patients with Inflammatory Bowel Disease.

ibdwatch

Immunosuppression Does Not Affect Antibody Concentrations to Measles, Mumps, and Rubella in Patients with Inflammatory Bowel Disease. Dig Dis Sci. 2018 Oct 13;: Authors: Caldera F, Misch EA, Saha S, Wald A, Zhang Y, Hubers J, Megna B, Ley D, Reichelderfer M, Hayney MS Abstract BACKGROUND: The Advisory Committee on Immunization Practices (ACIP) recommends using the immunization record and not serologic testing to determine immunity against measles and rubella in the general population, due to potential false negatives. However, it is unknown whether the immune response is less durable among…

Read More

Alternative Splice Forms of CYLD Mediate Ubiquitination of SMAD7 to Prevent TGFB Signaling and Promote Colitis.

ibdwatch

Alternative Splice Forms of CYLD Mediate Ubiquitination of SMAD7 to Prevent TGFB Signaling and Promote Colitis. Gastroenterology. 2018 Oct 10;: Authors: Tang Y, Reissig S, Glasmacher E, Regen T, Wanke F, Nikolaev A, Gerlach K, Popp V, Karram K, Fantini MC, Schattenberg JM, Galle PR, Neurath MF, Weigmann B, Kurschus FC, Hövelmeyer N, Waisman A Abstract BACKGROUND & AIMS: The CYLD lysine 63 deubiquitinase gene (CYLD) encodes tumor suppressor protein that is mutated in familial cylindromatosis, and variants have been associated with Crohn’s disease (CD). Splice forms of CYLD that…

Read More

Burden and Cost of Gastrointestinal, Liver, and Pancreatic Diseases in the United States: Update 2018.

ibdwatch

Burden and Cost of Gastrointestinal, Liver, and Pancreatic Diseases in the United States: Update 2018. Gastroenterology. 2018 Oct 10;: Authors: Peery AF, Crockett SD, Murphy CC, Lund JL, Dellon ES, Williams JL, Jensen ET, Shaheen NJ, Barritt AS, Lieber SR, Kochar B, Barnes EL, Fan YC, Pate V, Galanko J, Baron TH, Sandler RS Abstract BACKGROUND & AIMS: Estimates of disease burden can inform national health priorities for research, clinical care, and policy. We aimed to estimate health care use and spending among gastrointestinal (GI) (including luminal, liver, and pancreatic)…

Read More
<< Go Back